Medical tech firm Enovis' Q2 sales beat expectations
Overview
Enovis Q2 net sales grow 7%, beating analyst expectations, per LSEG data
Adjusted EPS for Q2 beats consensus, indicating strong operational performance
Company reports Q2 net loss of $37 mln, reflecting profitability challenges
Outlook
Enovis expects 2025 revenue between $2.245 bln and $2.275 bln
Company forecasts 2025 adjusted EBITDA of $392-402 mln
Enovis updates full-year adjusted EPS guidance to $3.05-$3.20
Result Drivers
RECONSTRUCTIVE SALES - Reconstructive segment sales grew 11% year-over-year, driven by new product introductions
STABLE MARKETS - Stable end markets contributed to overall sales growth of 7%
NEW PRODUCTS - Encouraging momentum in new product introductions supported sales growth
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Sales | Beat | $564.54 mln | $554.60 mln (11 Analysts) |
Q2 Adjusted EPS | Beat | $0.79 | $0.72 (11 Analysts) |
Q2 Gross Margin |
| 59.3% |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Enovis Corp is $57.00, about 54.8% above its August 6 closing price of $25.76
Press Release: ID:nGNX6cwhG7
